Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
04:01pm, Tuesday, 12'th Aug 2025
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free defini
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th Aug 2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01:05pm, Thursday, 03'rd Jul 2025
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
12:30pm, Thursday, 12'th Jun 2025
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up
Top Cancer Stocks to Supercharge Your 2025 Portfolio
11:26am, Tuesday, 10'th Jun 2025
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
04:30pm, Friday, 30'th May 2025
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
05:54pm, Wednesday, 28'th May 2025
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) Oral presenta
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
12:45pm, Wednesday, 14'th May 2025
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Tuesday, 13'th May 2025
Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago.
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
04:01pm, Tuesday, 13'th May 2025
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
06:22pm, Thursday, 08'th May 2025
I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determ
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd May 2025
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent st
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
09:25am, Tuesday, 29'th Apr 2025
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clin
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
11:45am, Tuesday, 15'th Apr 2025
The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.
